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L-Dopa decarboxylase (DDC) is a pyridoxal 5-phosphate (PLP)-dependent enzyme 
that catalyses the decarboxylation of L-Dopa to dopamine (DA). DDC has been 
identified as a co-activator of Androgen Receptor (AR) and is considered to be a 
neuroendocrine marker for the detection of prostate cancer. The role of DDC in the 
pathogenesis of prostate cancer remains unknown. Recent studies have shown that 
carbidopa inhibits the DDC-dependent activation of AR. In this report, we have 
investigated the effect of two DDC inhibitors, namely carbidopa (α-methyl-
dopahydrazine) and NSD-1015 (3-hydroxybenzyl-hydrazine), on the survival of DU-
145 (Androgen Receptor-Independent) cells, as well as on the expression of DDC. 
The obtained cytotoxicity effects were compared with those obtained for the human 
neuroendocrine cell line SH-SY5Y, as well as in CHO cells expressing human DDC 
(CHO/DDC). Both carbidopa and NSD-1015 exerted considerable cytotoxic effects 
on DU-145 cells. Furthermore, carbidopa was shown to influence the expression of 
DDC on DU-145 cells. Interestingly, our results indicated that carbidopa and NSD-
1015 treated CHO/DDC cells demonstrated an impressive degree of cytotoxicity in 
the presence of these molecules, as compared to CHO cells which do not express 
human DDC. Our results provide evidence for involvement of DDC regulation in 
cytotoxicity and in Androgen–Receptor Independent prostate cancer cell survival. 
The mechanism of the observed carbidopa-induced cell death, in addition to the 
study of the involvement of DDC in AR-independent prostate cancer cell viability, are 
currently under investigation. 
 
Acknowledgments This research has been co‐financed by the European Union (European 
Social Fund – ESF) and Greek national funds through the Operational Program "Education 
and Lifelong Learning" of the National Strategic Reference Framework (NSRF) ‐ Research 
Funding Program: THALES. Investing in knowledge society through the European Social 
Fund (THALES – UoA – BIOPROMO, MIS 377046). 
 
